Compare CLST & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | KALA |
|---|---|---|
| Founded | 1922 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 55.8M |
| IPO Year | 2021 | 2017 |
| Metric | CLST | KALA |
|---|---|---|
| Price | $16.59 | $1.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 2.2K | ★ 172.1K |
| Earning Date | 04-30-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.79 | 67.39 |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $110.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.25 | $0.07 |
| 52 Week High | $18.16 | $20.58 |
| Indicator | CLST | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 35.36 |
| Support Level | $16.40 | $0.32 |
| Resistance Level | $16.98 | $1.81 |
| Average True Range (ATR) | 0.21 | 0.41 |
| MACD | 0.00 | -0.20 |
| Stochastic Oscillator | 44.00 | 4.77 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It operates in one reportable segment, which generates income principally from interest on loans and investment securities, as well as from fees charged in connection with various loan and deposit services.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.